PRDS(Delisted)
Pardes BiosciencesยทNASDAQ
--
--(--)
PRDS Profile
Pardes Biosciences, Inc.
A clinical-stage biopharmaceutical company that develops novel oral antiviral drug candidate for SARS-CoV-2 infections and COVID-19 disease
2173 Salk Avenue, Suite 250, PMB#052, Carlsbad, CA 92008
--
Pardes Biosciences, Inc., was incorporated in Delaware on August 21, 2020. Pardes Biosciences is a clinical-stage biopharmaceutical company that aims to help address the scale of the pandemic that began with COVID 19. They are applying modern reversible covalent chemistry as a starting point for the discovery and development of new oral drug candidates, while reimagining the patient's journey to obtain these drugs. The company's lead product candidate, PBI-0451, is being developed as a direct-acting oral antiviral drug for the treatment and prevention of SARS-CoV-2 infection, the virus that causes COV19.
